Teva Pharmaceuticals plans to eliminate 250 jobs within its contract development and manufacturing organization (CDMO) unit over the next two years, according to a report by the Israeli business news outlet Globes. The operational downscaling comes as Teva faces a prolonged search to secure a new buyer for its active pharmaceutical ingredient division, known as Teva Active Pharmaceutical Ingredients (TAPI), following its strategic decision to divest the unit in January 2024.
The documented regional staffing adjustments, Middle Eastern geopolitical headwinds, and corporate portfolio innovations feature:
-
Staffing Reductions and Trade Union Coordination:
-
Impacted Manufacturing Sites: The job cuts will predominantly impact Teva’s manufacturing facility located in Neot Hovav, an industrial zone near Beer Sheva, Israel. TAPI currently maintains a global workforce of approximately 4,100 employees, representing a contraction from the 4,300 personnel registered when the planned divestiture was first made public.
-
Labor Relations Alignments: TAPI management noted that the downsizing workflow is being executed in full alignment and cooperation with employee representatives and the Histadrut (the General Federation of Labor in Israel, the nation’s largest trade union collective). The strategic objective is to preserve the long-term operational and financial stability of the chemical manufacturing unit within Israel.
-
-
Geopolitical Interruption Risks and Executive Transitions:
-
Supply Chain and Logistical Disruption: The transaction lifecycle for TAPI is navigating intense geopolitical headwinds driven by the conflict involving Iran. Military tensions across the Middle East and the naval blockade of the Strait of Hormuz have severely disrupted global API transit routes, while surging energy overheads impose acute financial pressure on pharmaceutical freight. In March, Israeli missile strikes reportedly compromised a manufacturing site owned by Tehran-based pharma leader Tofigh Daru.
-
Retirement of Unit CEO: Both the structural divestiture and the newly announced layoffs will transfer to incoming corporate leadership. R. Ananthanarayanan, Ph.D., who was brought on by Teva in 2023 to spearhead the specialized API division, is formally scheduled to retire as CEO of TAPI and exit the company on July 3, 2026.
-
-
Macro Restructuring Initiatives and Pivot to Innovative Therapeutics:
-
Global Financial Overhaul: The targeted TAPI layoffs run parallel to a broader corporate restructuring blueprint unveiled by Teva last fiscal year, aimed at yielding $700 million in cumulative savings by 2027 by cutting approximately 8% of its 30,000 global workforce (TAPI was initially exempted from this baseline program).
-
Evolving Product Portfolios: Historically structured as a generic drug manufacturer, Teva is aggressively pivoting capital toward patent-protected innovative medicines. In the first quarter of 2026, its flagship innovative brands—the tardive dyskinesia therapy Austedo, the migraine intervention Ajovy, and the long-acting schizophrenia treatment Uzedy—delivered a combined 41% year-over-year revenue surge in local currencies.
-
Pipeline Extensions and M&A Transactions: Teva’s regulatory filing for a once-monthly, long-acting formulation of olanzapine engineered for schizophrenia is currently undergoing active FDA review. Supplementing this pipeline, the Israeli pharma company deployed $700 million upfront in April to acquire Emalex Biosciences, securing a novel dopamine D1 receptor antagonist positioned for an FDA submission for Tourette syndrome later this year.
-
Source: https://www.fiercepharma.com/manufacturing/teva-lay-250-api-unit-search-new-owner-drags-report